Update on ocular cicatricial pemphigoid and emerging treatments

• Published in: Survey of ophthalmology Vol. 61; no. 3; pp. 314 - 317
• Main Authors: Queisi, Munther M., MB, Zein, Mike, MB, Lamba, Neerav, MD, MBA, Meese, Halea, MS, Foster, Charles Stephen, MD
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.05.2016
• Subjects: alkylating agents; Alkylating Agents - therapeutic use; biologic agents; Biological Factors - therapeutic use; chemotherapy; Conjunctival Diseases - drug therapy; Conjunctival Diseases - pathology; Dapsone - therapeutic use; Humans; Immunomodulation; immunomodulatory therapy; Immunosuppressive Agents - therapeutic use; Methotrexate - therapeutic use; mucus membrane pemphigoid; Mycophenolic Acid - analogs & derivatives; Mycophenolic Acid - therapeutic use; ocular cicatricial pemphigoid; Ophthalmology; Pemphigoid, Benign Mucous Membrane - drug therapy; Pemphigoid, Benign Mucous Membrane - pathology; alkylating agents; biologic agents; immunomodulatory therapy; chemotherapy; ocular cicatricial pemphigoid; mucus membrane pemphigoid
• ISSN: 0039-6257; 1879-3304
• DOI: 10.1016/j.survophthal.2015.12.007

Abstract Mucous membrane pemphigoid is a systemic disorder that primarily affects mucous membranes. When localized to the conjunctiva, it is known as ocular cicatricial pemphigoid, a potentially blinding disease. Ocular cicatricial pemphigoid is an indication for systemic immunosuppressive treatment to achieve adequate remission. Immunosuppressive agents are selected with a “stepladder” approach, commencing with medications having the fewest side effects. We provide an update of the literature on immunomodulatory agents since 2011 as additional treatment modalities have been explored in the last 4 years.